Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bifido Co. Ltd. (238200:KRX), powered by AI.
Bifido Co. Ltd. is currently trading at ₩2,420. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bifido Co. Ltd. on Alpha Lenz.
Bifido Co. Ltd.'s P/E ratio is -102.7.
“Bifido Co. Ltd. trades at a P/E of -102.7 (undervalued) with modest ROE of -0.4%. 3Y revenue CAGR of 10.5% highlights clear growth momentum.”
Ask for details →Bifido Co. Ltd. specializes in the production and distribution of probiotics and health-related products. The company focuses primarily on the development of food supplements and functional foods that promote gut health through beneficial bacteria. Dedicated to enhancing consumer well-being, Bifido Co. Ltd. operates within the health and wellness sector, catering to a growing demand for dietary supplements and preventive health solutions. Leveraging state-of-the-art research facilities and collaboration with scientific institutions, the company strives to advance its product portfolio and effectiveness. The role of Bifido Co. Ltd. in the financial market is amplified by the increasing global awareness of healthy lifestyles and preventive healthcare, making it a noteworthy participant in the biotechnology and life sciences industry. With its commitment to innovative probiotic solutions, Bifido Co. Ltd. has strategically positioned itself in both domestic and international markets as a leader in the holistic health movement.
“Bifido Co. Ltd. trades at a P/E of -102.7 (undervalued) with modest ROE of -0.4%. 3Y revenue CAGR of 10.5% highlights clear growth momentum.”
Ask for details →Bifido Co. Ltd. (ticker: 238200) is a company listed on KRX in the Consumer Defensive sector (Packaged Foods). It has approximately 83 employees. Market cap is $19.8B.
The current price is ₩2,420 with a P/E ratio of -102.71x and P/B of 0.43x.
ROE is -0.42% and operating margin is 7.13%. Annual revenue is $19.7B.